(Q34555011)

English

Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1

object named as

Monique J Roobol

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Dina W Roobol

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Fritz H Schröder

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

1 February 2005

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

65

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

343-346

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.09.046

7 January 2021

The story of the European Randomized Study of Screening for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.09.046

7 January 2021

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.09.046

7 January 2021

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.09.046

7 January 2021

Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands).

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.09.046

7 January 2021

Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.09.046

7 January 2021

Natural history of PSA increase with and without prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.09.046

7 January 2021

Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.09.046

7 January 2021

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.09.046

7 January 2021

Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.09.046

7 January 2021

Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.09.046

7 January 2021

Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam).

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.09.046

7 January 2021

Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.09.046

7 January 2021

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.09.046

7 January 2021

Identifiers

10.1016/J.UROLOGY.2004.09.046

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34555011&oldid=1753137866"